Company ProfilePremium

Life Healthcare Group Holdings Limited

Company Profile Analysis

Ticker: LHC.JO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Life Healthcare Group Holdings Limited - Company showcase

Year Founded & Workforce

1983

16,549 Employees

Life Healthcare Group Holdings Limited logo

Life Healthcare Group Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Life Healthcare Group Holdings Limited Overview

Life Healthcare is one of South Africa's three dominant private hospital operators, alongside Netcare and Mediclinic. Following its exits from Poland, the UK and Europe, and global radiopharmaceuticals between 2021 and 2025, it is now a pure-play Southern African healthcare services group.

Core assets: - 42 acute hospitals with 8 085 acute beds;

  • a growing complementary-services platform spanning mental health, acute rehabilitation, renal dialysis, oncology, diagnostic imaging, nuclear medicine and radiopharmaceutical production;

  • a smaller healthcare-services arm comprising government-contracted chronic care (Life Nkanyisa) and occupational health (Life Health Solutions).

Economics: - The group is highly dependent on private medical schemes; c. 64% of revenue comes from three funders.

  • Its normalised EBITDA margin (c. 15–16%) is structurally below Netcare's (c. 18.6%).

Balance sheet: After returning roughly R13 billion in special dividends since 2024, the balance sheet is lightly geared (0.93x net debt to EBITDA at March 2026).

Investment debate: The investment case now rests on:

  • recovering occupancy;

  • delivering a R400 million cost-saving programme;

  • greenfield and brownfield growth such as Life Paarl Valley; and

  • optionality from up to US$400 million of LMI earn-outs.

Overhang: These are set against persistent regulatory risk from National Health Insurance (NHI).


What the company does. Life Healthcare owns and operates private healthcare facilities, overwhelmingly in South Africa. It also operates a hospital in Botswana and renal dialysis units in Namibia.

The group reports three operating segments plus a corporate segment [S3]:

Hospitals: acute hospitals and day facilities.

Complementary services: mental health, acute physical rehabilitation, renal dialysis, oncology and diagnostics (MRI, CT, PET-CT, SPECT and nuclear medicine).

Healthcare services: Life Nkanyisa (government-contracted long-term care) and Life Health Solutions (occupational health, wellness, emergency medical services and primary care).

International: now only a residual UK holding entity carrying the Piramal liability and LMI-related receivables.

Company's own description. In its FY2025 and H1-2026 reporting the group frames itself around three ideas [S3]:

  • being a leading provider of value-based care, delivered through innovative contracting and reimbursement models;

  • offering a diversified range of services, extending into diagnostics and adjacent lines of business;

  • being people-centred and patient-insight driven, supported by data and technology.

Its stated purpose is "Making life better" [S26]. Its strategy is branded "Grow, Drive, Optimise", aimed at increasing market share, revenue and returns (MRR) [S2].

Business model and revenue model. The business is essentially 100% service revenue; there is no material product, subscription or licensing income after the LMI disposal.

H1-2026 revenue disaggregation [S3]:

Timing of recognition: R9 263 million (74.6%) of H1-2026 revenue was recognised over time (patient stays) and R3 159 million (25.4%) at a point in time (pharmaceuticals, consumables and discrete procedures) [S3].

Price setting: Hospital revenue is driven by paid patient days (PPDs) multiplied by revenue per PPD. Revenue per PPD is set by annual tariff negotiations with medical schemes and by case mix.

  • FY2025: average tariff increase 5.1% plus a 0.7% case-mix benefit, giving +5.8% revenue per PPD [S2].

  • H1-2026: average tariff increase fell to 3.3% [S3].

Alternative reimbursement: Value-based contracts and integrated care products (ICPs), for example renal, provide bundled or alternative reimbursement [S2].

Funder networks: Funder and network channels (designated-service-provider networks) accounted for 35% of PPDs in FY2025 [S2].

Value chain position. Life sits at the provider tier of the private healthcare value chain:

Downstream: It sits between funders (medical schemes and administrators) and patients.

Upstream: It buys from pharmaceutical and consumable suppliers (FY2025 drugs and consumables were about a quarter of revenue; H1-2026 R3 337 million, or 26.9%) and employs nursing staff (employee costs R4 996 million, or 40.2% of H1-2026 revenue) [S3].

Specialists: Under South African practice restrictions, specialists are largely independent practitioners admitting to Life facilities rather than employees. This makes doctor recruitment and retention a core commercial lever, with c. 140 recruits targeted for FY2026 [S4].

Customer types and end-markets.

Insured private patients: the predominant customer group. In 2024 South African medical schemes covered c. 9.17 million beneficiaries [S25].

Government: provincial health departments contract Life Nkanyisa beds and some hospital services.

Corporates: mining and industrial employers buy on-site occupational health.

Cash-paying patients: a small segment.

End-markets: acute inpatient care, emergency care (655 745 emergency-unit visits in FY2025 [S2]), cardiac care, mental health, rehabilitation, renal replacement therapy, oncology, diagnostic imaging and nuclear medicine.

Independent characterisation. Analytically, Life is a mature, capital-intensive, regulated-price business with high operating leverage to occupancy. Each percentage point of occupancy moves margin meaningfully, which is why management targets c. 70%. Exposure to medical-scheme membership growth is limited because scheme membership has been flat at c. 15% of the population for years [S25].

Where growth comes from: Organic growth relies on tariff inflation, case-mix and modest volume gains. Incremental growth is coming from complementary services, which grew revenue 24.7% in FY2025 [S2], and from greenfield and brownfield capacity.

Why the 2023–2025 disposals matter: They converted a complex, internationally diversified group into a simpler but less diversified, rand-only franchise. The resulting cash was returned to shareholders rather than reinvested.

Strategy

Stated strategy themes (FY2025 results; FY2025 integrated report). The strategy is "Grow, Drive, Optimise", with the objective of delivering high-quality, cost-effective care while increasing market share, revenue and returns [S2].

Medium-term financial targets and guidance. Management has not published formal multi-year margin or return targets in the sources reviewed. Evolution of FY2026 guidance:

Sources: [S1][S2][S4]. The May 2026 cut to revenue and occupancy guidance was cited by analysts as the reason for the 5% share-price fall on results day [S20].

Products & Services

Pricing across the hospital and complementary portfolio is tariff-based. Tariffs are negotiated annually with medical schemes or set by contract with government and corporate clients. List prices are not publicly disclosed.

Hospitals segment

OfferingDescription and capabilitiesTarget customerYear / statusPricing modelFlagship / named examples
Acute hospital network42 facilities, 8 085 acute beds, 293 theatres; general ward, ICU and high-care. ICU occupancy 84.3% in FY2025; 46 ICU beds added over two years [S2]Medical-scheme members; network/DSP patientsOngoing; 89 acute beds planned for FY2026, revised to 87 [S1][S4]Per-diem / fee-for-service tariffs; ward and theatre fees; pharmacy and consumablesLife Eugene Marais (Pretoria; 14 theatres, hybrid theatre, neuro-spinal rehab) [S31]; Life Mt Edgecombe; Life Rosepark; Life Peglerae; Life Bedford Gardens (144 beds) [S18]
Emergency units39 emergency units; 655 745 visits in FY2025 [S2]Walk-in and ambulance patients; the main admissions channelLife Peglerae emergency unit upgraded in FY2025 [S2]Facility fee plus admissionLife Peglerae Hospital (Rustenburg)
Cardiac network17 cathlabs and 5 vascular labs across a 15-facility cardiac network [S2]Cardiology / vascular patientsNew cathlab at Life Mt Edgecombe and new vascular lab at Life Rosepark planned for FY2026 [S2]Procedure-based tariffsLife Mt Edgecombe (Durban); Life Rosepark (Bloemfontein)
Theatre and surgical services293 theatres; theatre minutes +2.2% in FY2025; medical/surgical revenue split 54/46 in FY2025 [S2]Surgeons and specialistsOngoingTheatre-minute tariffs—
Day facilities5 day facilities (89 beds, 15 theatres) [S2]Low-acuity surgical cases moving out of hospitalOngoingDay-case tariffs; alternative reimbursement—
New greenfield hospitalLife Paarl Valley Hospital: 140 beds in a lodge-style setting; includes the only cardiac cathlab in the area [S19]Western Cape Winelands, which is growing and attracting affluent retireesUnder construction; opening FY2027 (H2 2027) [S4][S19]Standard tariffsLocated between Paarl and Franschhoek (corner Fraaigelegen Road and R301)

Complementary services segment

OfferingDescription and capabilitiesTarget customerYear / statusPricing modelFlagship / named examples
Mental health9 facilities, 607 beds. Occupancy 76.6% in FY2025 [S2][S5]Psychiatric and addiction patients (medical-scheme PMB conditions)OngoingPer-diem tariffsLife Hunterscraig Private Hospital (Gqeberha) [S20]
Acute physical rehabilitation7 units, 287 beds; 24 beds added in FY2025 [S2]Post-stroke, spinal, trauma and orthopaedic patients40 beds planned for FY2026, revised to 64 [S1][S4]Per-diem tariffs—
Renal dialysis (Life Renal Dialysis / Life Renal Care)74 facilities, 1 089 stations [S2]. Includes 41 ex-Fresenius South African units (acquired 1 Apr 2024) and Namibian units (FY2025)End-stage kidney disease patientsTreatments +9.3% in H1-2026; positive normalised EBITDA in H1-2026 after prior losses [S3]. 20 renal stations planned for FY2026 [S2]Per-session tariffs; renal integrated care product (ICP) bundles [S2]Three stand-alone renal sites closed and one being sold in H1-2026 [S3]
Oncology5 facilities, 32 chemotherapy units, 6 linear accelerators [S2]Cancer patientsOngoingTreatment-based tariffs—
Diagnostic imaging8 in-hospital imaging sites and 3 outpatient facilities (MRI, CT, X-ray); 2 imaging sites acquired in FY2025. Imaging volumes +9.0% in FY2025 and +4.2% in H1-2026 [S2][S3]Referring doctors; inpatients and outpatientsBuilt through acquisitions (2022–2025)Non-clinical facility fees. Radiologists' professional fees are separate under South African practice structuresEast Coast Radiology (KZN, 2022); Eugene Marais Radiology (2022) [S13][S31]
Nuclear medicine / PET-CT3 PET-CT sites (Gauteng; acquired with TheraMed Nuclear in 2023), using PET-CT and SPECT-CT [S2][S31]Oncology and cardiology referrals3 more PET-CT sites opening during FY2026 [S4]Scan-based tariffs—
Radiopharmaceutical manufacturing2 cyclotrons built in partnership with Axim to produce radiotracers locally [S2][S3]Life's own PET-CT network and third partiesAwaiting final regulatory sign-off; commercial production expected after approval [S4]Product supply pricing not disclosedGauteng cyclotrons (Axim joint venture)

Healthcare services segment

OfferingDescription and capabilitiesTarget customerYear / statusPricing modelNotes
Life Nkanyisa7 facilities, 2 531 beds, 4 provinces [S2]. Long-term chronic care under contract to provincial governmentsProvincial departments of healthLost three contracts in FY2024; revenue pressure continuing [S9][S1]Government contract per-bed / per-day ratesCredit-loss provision reversal in H1-2025 flattered the prior period [S3]
Life Health SolutionsOccupational health, wellness, emergency medical services and primary care: 198 on-site clinics, 12 off-site clinics, 14 mobile units, 8 EMS sites [S2]Mining and industrial employersLost significant contracts; impairments of R63m (FY2025) and R29m (H1-2026) [S3]Corporate service contracts—
MyLife Clinic (primary care)Low-cost primary care consultation offering, reportedly at R300 including basic medication [S29]Uninsured / cash-paying patients—Flat feeSource is a third-party commentary

Cross-cutting and other

OfferingDescriptionStatus
Value-based care / integrated care products (ICPs)Alternative reimbursement contracts with funders. Renal ICP reported "excellent outcomes" in FY2025 [S2]Ongoing
Funder / network channelDesignated-service-provider (DSP) arrangements; 35% of PPDs in FY2025 [S2]Ongoing
Learning centres (nursing education)7 learning centres; R76.8m invested in nurse training in FY2025 [S2][S26]Ongoing
Specialist training programme9-year programme to train 40 surgical specialists, 35 medical specialists and 40 sub-specialists. Total investment R450m; management targets a 22% return over the period [S2]Initiated FY2025
LMI African rightsRetained right to manufacture, commercialise and distribute LMI products (e.g. NeuraCeq) in Africa [S2][S3]Not yet monetised (nil revenue FY2025 and H1-2026)

Financial Narrative

Southern Africa comparable operations (the continuing business)

Sources and derivations:

  • FY2022–FY2023 [S10]; FY2024–FY2025 [S2].

  • FY2021 is derived from aggregator segment data [S8] (hospitals and complementary R17.57bn plus healthcare services R1.46bn; EBITDA aggregated including corporate). It is approximate.

Growth summary:

  • Revenue CAGR FY2021–FY2025 (derived): c. 7.2% per year. FY2022–FY2025 CAGR: c. 7.9%.

  • Normalised EBITDA CAGR FY2021–FY2025 (derived): c. 4.3% per year.

  • The gap between revenue and EBITDA growth reflects margin erosion of c. 180 basis points.

Revenue growth (Southern Africa):

FY2022 revenue growth is derived. FY2023–FY2025 growth rates are company-reported (FY2024 EBITDA reported as −0.9% on the company basis) [S9][S10][S1].

Group as published and IFRS view (not like-for-like)

How to read this table:

Revenue as published: [S11][S10][S9][S1]:

  • FY2021–FY2022 include AMG and LMI.

  • FY2023 excludes AMG.

  • FY2024 includes LMI.

  • FY2025 excludes LMI.

Normalised EBITDA as published: FY2021–FY2022 are on a continuing basis including AMG [S11]. FY2023 is company-reported [S10]. FY2024 is derived from the company's reported +19.9% growth on FY2023, which included the LMI RM2 sublicence gain [S9]. FY2025 is from [S2].

  • Gross profit, reported EBITDA, EBIT, pre-tax profit, net income, diluted EPS and margins: aggregator [S7]. The aggregator restates FY2022 onward to continuing operations, so FY2021 is not on the same basis.

Basic EPS: FY2021–FY2022 aggregator [S7]; FY2023–FY2025 company [S9][S1].

Dividends: company [S1][S2][S9][S10][S11].

Earnings-quality metrics (company-reported):

  • FY2023 HEPS is derived from FY2024's reported +73.4% growth [S9].

  • FY2024 NEPS restated to exclude LMI was 91.1 cents, so FY2025 NEPS growth was +10.1% [S1].

  • FY2025 continuing HEPS was −93.9 cents reported, or 107.1 cents pro forma excluding the R2 881m Piramal fair-value loss (+14.7% versus restated FY2024 of 93.4 cents) [S1].

H1-2026 snapshot [S3]:

  • Revenue R12 422m (+2.4%); normalised EBITDA R1 957m (+5.2%, margin 15.8%).

  • Operating profit before non-trading items R1 290m (+8.4%).

  • Attributable profit R771m (versus a R2 220m loss in H1-2025); NEPS 53.1 cents (+8.4%); interim dividend 23 cents (+9.5%).

FY2025 income statement walk (company, ZAR m) [S2]:

  • Revenue 25 104 → normalised EBITDA 3 845 (15.3%) → EBITA 2 708 → amortisation (175) → operating profit before non-trading items 2 533.

  • Non-trading items: Piramal fair-value loss (2 881); other non-trading (160), including R211m impairments.

  • Below the line: net finance costs (122); associates 10 → loss before tax (620); tax (721); non-controlling interest (107) → attributable loss from continuing operations (1 448).

  • Pro forma excluding Piramal: attributable profit R1 433m (+1.3%).

Balance sheet

Source: aggregator [S7]. FY2024–FY2025 debt and cash reconcile to the company's figures [S2].

Two distortions to note:

FY2023: AMG's assets and liabilities were classified as held for sale, which inflates working capital (R24.4bn of other current assets) and removes AMG goodwill from the goodwill line.

FY2025 total assets: R25 690m in the financial statements versus R24 186m in the company presentation. The difference is the R1 504m contingent-consideration receivable, which the presentation nets off [S2][S3].

Net debt including the Piramal liability [S2][S3]:

  • At 30 Sep 2025, reported net debt was only R141m, because LMI proceeds had been withheld to pay Piramal.

  • Including the R2 631m Piramal liability then due, adjusted net debt was R2 772m (0.77x EBITDA).

  • At 31 Mar 2026, after paying US$148m (R2 490m) to Piramal, net debt was R3 683m (0.93x covenant basis). A residual Piramal liability of R772m remains (cap: US$200m in total, of which US$148m has been paid).

H1-2026 balance sheet [S3]:

  • Total assets R23 434m; cash R1 131m.

  • Interest-bearing borrowings R4 814m (R4 659m non-current, R155m current); equity R11 943m.

  • Contingent-consideration receivable R1 526m, comprising LMI earn-outs and milestones of R1 361m and the Fresenius clawback of R165m.

Cash flow

Source: aggregator [S7]. Life does not run open-market buyback programmes; share purchases relate to employee incentive schemes.

Company-defined cash flow (continuing operations) [S2]:

FY2024 cash conversion is derived. FY2025 is company-reported [S1].

H1-2026 cash flow [S3]:

  • Cash generated from operations fell 32.9% to R1 315m. Working-capital outflow was R633m, after a R466m inflow in H2-2025, and staff-scheme cash settlement was R152m.

  • Capex was R722m (R525m replacement, R197m growth).

  • R2 490m was paid to settle financial liabilities (Piramal).

  • New notes raised R1 500m; bank loans of R750m were repaid.

Ratios

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Southern Africa revenue (ZAR Mn)

19,03019,97121,98523,67425,104

Southern Africa normalised EBITDA (ZAR Mn)

3,2553,4783,7073,6713,845

Southern Africa normalised EBITDA margin (%)

17.117.416.915.515.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Southern Africa revenue growth (%)

4.910.17.76.0

Southern Africa normalised EBITDA growth (%)

6.96.6-1.04.7

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Group revenue as published (ZAR Mn)

26,88528,20622,64125,51925,104

Group normalised EBITDA as published (ZAR Mn)

5,0515,0393,5944,3093,845

Gross profit (ZAR Mn)

8,3545,8736,4816,6927,057

Reported EBITDA (ZAR Mn)

4,4253,0823,3693,3383,543

Operating profit EBIT (ZAR Mn)

2,9012,3192,4892,4122,528

Pre-tax profit continuing (ZAR Mn)

2,4092,1911,9112,170-620

Net income attributable total ops (ZAR Mn)

1,7541,5312644,8273,864

Basic EPS total ops (ZAR cents)

12110618.3328.8263.0

Diluted EPS total ops (ZAR cents)

12010518329263

Ordinary dividend per share (ZAR cents)

2540445056

Special dividend per share (ZAR cents)

000670235

Gross margin (%)

30.8728.3028.3127.9527.79

Operating margin (%)

10.7211.1810.8710.079.95

Net margin (%)

6.487.381.1519.8114.87

Per-Share Data

MetricFY2023FY2024FY2025

HEPS total operations (ZAR cents)

88.2152.9-112.1

NEPS continuing as published (ZAR cents)

89.1132.3100.3

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (ZAR Mn)

40,78142,23845,61524,34425,690

Cash and equivalents (ZAR Mn)

2,6722,8028462,4623,810

Short-term debt incl current leases (ZAR Mn)

2,1451,5612,1791,027187

Long-term debt incl leases (ZAR Mn)

10,91412,12411,0103,3943,764

Total debt (ZAR Mn)

13,05913,68513,1894,4213,951

Net debt (ZAR Mn)

10,38710,87512,3271,959141

Total equity (ZAR Mn)

19,17119,86021,28913,51412,142

Goodwill and intangibles (ZAR Mn)

16,38316,5143,2873,5702,333

Working capital (ZAR Mn)

-47313518,2162,2651,419

Book value per share (ZAR)

12.4212.9814.048.697.95

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (ZAR Mn)

5,1424,1844,6704,8195,025

Capex outflow PPE (ZAR Mn)

1,7071,2631,2131,2971,638

Free cash flow (ZAR Mn)

3,4352,9213,4573,5223,387

Dividends paid (ZAR Mn)

05876169,4725,233

Treasury share purchases for schemes (ZAR Mn)

31302121285407

Disposal proceeds (ZAR Mn)

00019,4665,649

Cash Flow and Margin Analysis (%)

MetricFY2024FY2025

Cash generated from operations (ZAR Mn)

3,7134,598

Maintenance capex (ZAR Mn)

1,1661,360

Growth capex (ZAR Mn)

200447

Company-defined free cash flow (ZAR Mn)

1,2781,745

Ordinary dividends paid (ZAR Mn)

668758

Special dividends paid (ZAR Mn)

8,8044,475

Cash conversion (% of normalised EBITDA)

101.1119.6

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

Return on equity (%)

9.447.636.948.82-10.45

Return on assets (%)

4.343.493.544.316.32

Return on invested capital (%)

6.865.225.786.9518.22

Current ratio (x)

0.941.022.631.431.20

Debt to equity (x)

0.680.690.620.330.33

Net debt to EBITDA covenant basis (x)

1.821.892.000.450.01

Interest coverage EBIT to interest (x)

5.36.84.15.77.0

Asset turnover (x)

0.650.500.520.691.01

Returns & Leverage Ratios (%)

MetricFY2024FY2025H1-2026

ROCE (%)

20.017.817.8

Working Capital (Days)

MetricFY2023FY2024FY2025

Days sales outstanding (days)

49.754.644.8

Days inventory outstanding (days)

10.09.98.1

Days payables outstanding (days)

38.840.939.7

Cash conversion cycle (days)

20.923.613.2

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

Southern Africa (ZAR Mn)

19,03019,97121,98523,67425,104

International AMG UK and Europe (ZAR Mn)

7,4707,680000

International LMI global radiopharma (ZAR Mn)

3855556561,8450

Total as published (ZAR Mn)

26,88528,20622,64125,51925,104

Region Margins & Growth (%)

RegionFY2022FY2023FY2024

Southern Africa growth (%)

4.910.17.7

LMI growth (%)

44.218.2181.3

Share Price and Market Valuation

MetricFY2021FY2022FY2023FY2024FY2025

Dividend-adjusted FY-end share price (ZAR)

10.017.729.2811.6610.99

Market capitalisation FY-end (ZAR Mn)

33,13125,08629,25023,04316,714

Enterprise value FY-end (ZAR Mn)

45,48437,06143,61218,01421,181

P/E (x)

18.8916.39110.804.864.43

EV/EBITDA (x)

10.2812.0312.955.405.98

EV/Sales (x)

1.681.791.910.750.83

P/B (x)

1.731.261.371.711.38

Dividend yield (%)

2.505.184.744.295.10

Share Price & Returns

HorizonReturnStart date

1-year

+10.8%

30 Sep 2025

3-year

+31.3%

29 Sep 2023

5-year

+21.7%

30 Sep 2021

Valuation Snapshot

MultipleValue

Trailing P/E

12.98x (basis not fully disclosed)

Forward P/E

9.52x

EV/EBITDA

5.67x

EV/Sales

0.85x

P/B

1.46x

Dividend yield

5.75%

Source Details

SourceConsensusDate

TradersUnion aggregation

12-month average target ZAC 1 264 (high 1 330; low 1 160)

As of 29 Sep 2026

Simply Wall St

Consensus fair value c. R12.86 (range R12.30–R13.70); references a JPMorgan upgrade

—

MarketBeat (ADR)

Consensus "Hold"

—

Per-Share Data and Capital Markets Data

MetricFY2021FY2022FY2023FY2024FY2025

Interim dividend (ZAR cents)

015171921

Final dividend (ZAR cents)

2525273135

Special dividends (ZAR cents)

000670235

Total distributions (ZAR Mn)

36357963410,5654,270

Capital Markets

ItemDetail

Rating

National scale zaAAA (improved in FY2025). Agency, outlook and global-scale ratings (Moody's / S&P / Fitch) not publicly disclosed in sources reviewed

Covenant

Net debt to normalised EBITDA ceiling of 3.5x

Undrawn facilities

R1.8bn (Sep 2025 and Mar 2026)

Capital Instruments

InstrumentFY2026FY2027FY2028FY2029 plus

Bank debt and notes (ZAR Mn)

201,975500775

Lease liabilities (ZAR Mn)

16710591318

Total debt (ZAR Mn)

1872,0805911,093

Analyst Conclusions

Management guidance for FY2026 (as revised 28 May 2026) [S4]:

  • Revenue growth of c. 2%.

  • PPDs relatively flat; occupancy c. 68%.

  • c. 140 specialists recruited.

  • Capex of c. R2.4bn.

  • Continued EBITDA margin improvement within a R400m, three-year savings programme.

  • Capacity additions: 87 acute beds, 64 rehab beds, a cathlab, a vascular lab and three PET-CT sites.

  • Cyclotron commercial production after regulatory approval.

  • Life Paarl Valley Hospital opening in FY2027.

Implied consensus growth (indicative):

  • Aggregator data suggest a forward P/E of c. 9.5x [S7].

  • One aggregator projects revenue growth of c.

  • Detailed sell-side consensus for EPS and EBITDA is not publicly disclosed in sources reviewed.

Bull case:

  1. Operating leverage on recovery. Q2-2026 acute occupancy exceeded 70% even as H1 averaged 67.0% [S3]. If funder disruption fades and occupancy returns to c. 70%, the high-margin top-30 hospitals (96% of acute EBITDA) should drive margin expansion beyond the +50 basis points already delivered in H1-2026.

  2. Self-help plus mix. R400m of savings (c. 10% of FY2025 EBITDA) [S2], combined with complementary services that are again growing at double digits with recovering margins (19.0%) [S3], could close part of the c. 300 basis point margin gap to Netcare.

  3. Hidden optionality and valuation support. LMI earn-outs and RM2 milestones (up to US$400m plus up to €362.5m) are carried at only R1.4bn [S3]. The stock trades at c. 5.7x EV/EBITDA [S7], below the 6.3x LTM multiple implied for Mediclinic Southern Africa [S22], with a c. 5–6% dividend yield and low leverage.

Bear case:

  1. Structural volume stagnation. Insured lives are flat (9.17 million) [S25]. Funder stress, as with Sizwe Hosmed, and lower tariffs (3.3%) [S3] can quickly erase guidance, as the May 2026 cut showed.

  2. Margin structurally inferior. Margin fell from c. 17% to c. 15% over FY2021–FY2025 despite revenue growth. Renal integration issues, an optimisation-facility tail and Life Health Solutions impairments suggest execution risk [S2][S3].

  3. Regulatory and competitive overhang, with less diversification. NHI litigation remains unresolved [S23]. A Remgro-backed Mediclinic Southern Africa is now a focused competitor [S22]. With all revenue in rand, there is no offshore earnings hedge [S3].

Concluding analyst verdict.

Life Healthcare enters FY2027 as a fundamentally different company from the one that listed in 2010. Three years of disciplined disposals turned an over-extended international portfolio into a lean, lowly geared, Southern African hospital and complementary-services franchise. Shareholders received roughly R13 billion in special dividends along the way.

What is clear: The strategic logic is sound — sell assets at full value, return the cash, and refocus capital on domestic capacity where demand is visible (ICU, mental health, renal, oncology, nuclear imaging). The balance sheet (0.93x net debt to EBITDA, zaAAA national rating) gives management ample room to fund Life Paarl Valley, buy back leased properties and pursue bolt-ons without straining dividends.

What remains unproven: whether the remaining business can earn returns that justify a re-rating. Normalised EBITDA margin has slipped from c. 17% to c. 15%, against Netcare's c. 18.6%. The FY2026 guidance cut showed how exposed the model is to funder disruption and tariff settlements. The Fresenius renal acquisition has proved harder to integrate than planned. Healthcare services is shrinking.

Where the swing factors lie: Near-term upside depends on two levers management controls (cost savings and asset optimisation) and one it does not (occupancy recovery).

Valuation: At c. 5.7x EV/EBITDA and a c. 5–6% dividend yield, the market prices Life as an ex-growth utility with regulatory risk. That is undemanding relative to the c. 6.3x private-market benchmark Remgro paid for Mediclinic Southern Africa, and it ascribes little value to LMI earn-outs that could be worth multiples of their R1.4 billion carrying value.

Verdict: a value-and-yield holding with credible self-help upside, but with limited structural growth. Evidence that margins are sustainably moving back above 16%, and a benign NHI ruling, are the two conditions most likely to unlock a re-rating. Until then, risk-reward appears balanced to modestly positive, consistent with the prevailing "Hold" consensus.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationAgeRemuneration

Peter (Pete) Wharton-Hood

Group Chief Executive; executive director

Since 1 Sep 2020

Standard Bank (joined 1997; Group COO and Deputy CEO); Deutsche Bank (CEO and Chief Country Officer South Africa from 2013; head of operations for the global markets division; global COO of corporate and investment banking) [S19][S28]

BCom, University of the Witwatersrand (1989); CA(SA); Harvard Advanced Management Programme [S19][S28]

Born 1965 (c. 61) [S19]

Single-figure remuneration of R55.107m per the latest remuneration report (reported May 2026) [S19]. Bought 220 299 LHC shares on 1 Jul 2025 (c. R3.1m) [S27]

Pieter van der Westhuizen

Chief Financial Officer; executive director. Also responsible for IT and cyber since Apr 2024

With the group for more than 25 years; CFO since c. 2015; acting CEO Jan–Aug 2020 and previously on an earlier occasion [S28][S32]

Life Healthcare finance roles

CA(SA) [S3]

—

Sold 53 544 shares on 15 Jan 2025 [S27]

Adam Pyle

Chief Strategy and Growth Officer (from Apr 2024); formerly Chief Executive Southern Africa (more than 6 years)

23 years with the group; retired 1 Jun 2026; advisory role for 7 months covering strategy, stakeholder relations and M&A [S16][S32]

————

Joshila Ranchhod

Company Secretary

Current

————

“—” = not publicly disclosed.

Board & Management Changes

DateChange

Apr 2024

Life and AMG executive committees combined after the AMG sale. Pyle moves from CEO Southern Africa to Chief Strategy and Growth Officer; CFO takes on IT and cyber

5 Feb 2026

Pyle's early retirement announced, effective 1 Jun 2026; he steps down from the Group Executive Committee

1 Jun 2026

Brett Mill appointed to the board of Life Healthcare Funding, replacing Pyle

Aug 2022

Lars Holmqvist and Dr Jeanne Bolger appointed

Aug 2024

Dr Fareed Abdullah and Dr Raymond Campbell appointed; Joel Netshitenzhe and Lars Holmqvist to retire at the 2025 AGM

Feb 2025

Netshitenzhe and Holmqvist retire

7 Aug 2025

Announced that Prof Marian Jacobs and Dr Jeanne Bolger will retire at the 2026 AGM; Board Charter and Nominations and Governance Committee terms updated

19 Feb 2026

Jacobs (Chair, Clinical Committee) and Bolger retire; Abdullah becomes Clinical Committee Chair

Board of Directors

NameRoleAppointed / notes

Dr Victor Litlhakanyane

Independent non-executive Chairman

Chair-designate from Jul 2020. MBChB (University of KwaZulu-Natal, 1988); MBA (University of the Free State); MD of Bigen Africa Health

Peter Wharton-Hood

Chief Executive

2020

Pieter van der Westhuizen

Chief Financial Officer

—

Dr Fareed Abdullah

Independent non-executive director; Chairman of the Clinical Committee from Feb 2026

Appointed Aug 2024 (South African Medical Research Council background)

Dr Raymond Campbell

Independent non-executive director

Appointed Aug 2024

Caroline Henry

Independent non-executive director; member of the Social, Ethics and Transformation Committee

—

Paul Moeketsi (TP Moeketsi)

Independent non-executive director

Appointed Feb 2023

Audrey Mothupi-Palmstierna

Independent non-executive director; member of the Social, Ethics and Transformation Committee

—

Adv Mahlape Sello

Independent non-executive director; Chair of the Social, Ethics and Transformation Committee

—

Fulvio Tonelli

Independent non-executive director

Appointed Apr 2023. Also a director of Absa Group and Equites Property Fund, and chair of the Independent Regulatory Board for Auditors.

Major Shareholders

RankHolder
1

Public Investment Corporation (incl. Government Employees Pension Fund mandates)

2

Sanlam Investment Management

3

Industrial Development Corporation of South Africa

4

Old Mutual Investment Group South Africa

5

Investment Solutions

6

Norges Bank Investment Management

7

Investec Wealth and Investment Management

8

Lazard Asset Management (increased stake, Mar 2026)

Competitive Landscape

Competitors by Segment

SegmentCompetitors

Acute hospitals

Netcare; Mediclinic Southern Africa (Remgro); Lenmed; National Hospital Network (NHN) affiliates; Busamed; Clinix; Joint Medical Holdings (JMH); Melomed

Mental health

Netcare Akeso; Mediclinic mental health facilities

Day surgery

Mediclinic day clinics; independent day-hospital groups (e.g.

Primary / occupational care

Netcare Primary Care; Mediclinic's Intercare; ER24 (EMS)

Diagnostic imaging

Independent radiology practices

Peer Comparison FY2029

CompanyLatest revenueGrowthEBITDA marginFootprintPositioningSource

Life Healthcare

R25.1bn (FY Sep 2025)

+6.0%15.3%

42 acute hospitals, 8 085 acute beds; 74 renal sites

Diversified pure-play Southern Africa; lowest margin of the big three

[S1][S2]

Netcare

R26.3bn (FY Sep 2025)

+4.5%18.6%

Largest by revenue; acute occupancy c. 65.0%

Margin and digitisation leader; share buybacks (10.4% of shares since Sep 2023)

[S21]

Mediclinic Southern Africa

—

Southern Africa revenue +8% in the six months to Sep 2025

Not disclosed (Mediclinic Holdings group adjusted margin 15.7%, including Switzerland)

c. 50 hospitals, 15 day clinics, 6 sub-acute, 6 mental health; 3 hospitals in Namibia

Now 100% Remgro-owned (US$947m; LTM EV/EBITDA c. 6.3x)

[S22]

Lenmed

———

Hospitals in Gauteng, KwaZulu-Natal, Northern Cape, Eastern Cape

Independent group

[S24]

NHN network

———

Network of independent hospitals

Collective contracting

[S24]

Busamed

————

Independent

[S24]

Clinix

———

Township-focused hospitals

Affordable segment

[S24]

JMH

———

Durban

Independent

[S24]

Netcare Akeso

Within Netcare

——

Mental health

Mental health competitor

[S21]

Melomed

———

Western Cape

Relevant to Paarl expansion

General knowledge

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricLife Healthcare FY2025Netcare FY2025Mediclinic Holdings FY Mar 2026

Revenue

R25.1bn

R26.3bn

US$5.36bn (adjusted; includes Switzerland)

Revenue growth

6.0%4.5%11%

Normalised EBITDA margin

15.3%18.6%15.7%

Most recent half-year revenue growth

2.4% (H1-2026)

4.8% (H1-2026)

—

Most recent half-year EBITDA margin

15.8%18.8%—

R&D intensity

Not disclosed / not applicable

Not disclosed / not applicable

Not disclosed / not applicable

Net debt to EBITDA

0.77x adjusted (0.93x at Mar 2026)

1.1x—

“—” = not publicly disclosed.

Company Snapshot

16,549

Employees

1983

Founded

SWOT Analysis

Strengths

  • Strong balance sheet: Net debt to EBITDA of 0.93x (Mar 2026) against a 3.5x covenant; R1.8bn undrawn facilities; zaAAA national rating [S2][S3]
  • High cash conversion: Cash generated equal to 119.6% of normalised EBITDA in FY2025 [S1]
  • Concentrated profit pool in core hospitals: Top-30 hospitals: 88% of acute revenue, 96% of acute EBITDA, 72.0% occupancy [S2]
  • Broad complementary platform growing fast: Complementary revenue +24.7% in FY2025 and +13.7% in H1-2026; margin recovered to 19.0% [S2][S3]
  • Proven capital discipline and value realisation: AMG (c. R21bn) and LMI (up to US$755m) sales; R10.6bn (FY2024) and R4.3bn (FY2025) returned [S1][S9]
  • Critical-care capability: ICU occupancy 84.3% (FY2025) and 82% (H1-2026); 46 ICU beds added over two years [S2][S20]
  • Low-cost debt access: R1.5bn notes priced at 3-month JIBAR + 0.88% to + 0.94% (Mar 2026) [S3]

Weaknesses

  • Margin gap to the leading peer: Life 15.3% versus Netcare 18.6% normalised EBITDA margin (FY2025) [S1][S21]
  • Funder concentration: c. 64% of H1-2026 revenue from three customers [S3]
  • Underperforming asset tail: R211m impairments in FY2025; asset-optimisation list; Life Isivivana closed [S1][S2]
  • Declining healthcare-services division: Revenue −7.5% in FY2025; Life Health Solutions goodwill impaired (R63m + R29m) [S2][S3]
  • Earnings opacity from legacy LMI accounting: R2 881m Piramal loss in continuing operations; reported HEPS of −112.1 cents in FY2025 [S1]
  • Acquisition-diligence issues: Fresenius renal carve-out EBITDA discrepancy; R165m clawback and Namibia dispute [S3]
  • Loss of geographic and currency diversification: 100% Southern African revenue since FY2025 [S3]

Opportunities

  • Occupancy recovery leverage: Q2-2026 acute occupancy above 70% versus 67.0% for H1 [S3]
  • Cost programme: R400m savings over 3 years against FY2025 normalised EBITDA of R3 845m (c. 10%) [S2]
  • Greenfield and brownfield growth: Life Paarl Valley (140 beds, FY2027); 87 acute and 64 rehab beds in FY2026 [S4][S19]
  • Nuclear medicine vertical integration: 2 cyclotrons pending approval; 3 new PET-CT sites [S4]
  • LMI earn-out upside: Up to US$400m of earn-outs plus RM2 milestones of up to €362.5m and royalties; carried at only R1 361m [S3]
  • Property ownership: Buying leased hospitals (R350m property in FY2025; Bedford Gardens in 2026) reduces lease cost and risk [S3][S18]
  • Specialist pipeline: R450m training programme targeting 115 specialists, with a projected 22% return [S2]

Threats

  • NHI: Act signed May 2024; Constitutional Court judgment reserved (May 2026); more than a dozen further cases stayed [S23]
  • Funder distress: Sizwe Hosmed curatorship reduced H1-2026 PPDs; Life's PPDs −0.4% [S3][S24]
  • Tariff pressure: Average tariff increase fell from 5.1% (FY2025) to 3.3% (H1-2026) [S2][S3]
  • Stronger competitors: Netcare margin 18.8% (H1-2026); Remgro now 100% owns Mediclinic Southern Africa [S21][S22]
  • Stagnant insured market: 9.17m beneficiaries (+0.45%); cost per admission +9.88% pressures schemes [S25]
  • Government contract attrition: Life Nkanyisa contract losses in FY2024 [S9]
  • Litigation: Ongoing Fresenius dispute over renal acquisitions [S3]

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13 Jan 2025 (context)Binding agreement to sell LMI to Lantheus [S12]Sets up the FY2025 capital return
6 Mar 2025LMI classified as held for sale [S3]Accounting reclassification
22 May 2025H1-2025 results: revenue +8.1% to R12.1bn; R2.9bn Piramal fair-value charge produces an IFRS loss; interim dividend 21 cents (+10.5%) [S29]Shows the Piramal accounting hit
1 Jul 2025CEO buys 220 299 shares (c. R3.1m) [S27]Insider confidence signal
Mid-Jul 2025LMI conditions precedent met [S33]Clears the sale path
21 Jul 2025LMI disposal completed (US$355m upfront) [S3]Final international exit
7 Aug 2025R2.35 special dividend declared; board succession announced (Jacobs, Bolger) [S15]R3.4bn capital return
28 Aug 2025Council for Medical Schemes applies for Sizwe Hosmed curatorship (provisional order Sep; confirmed 9 Oct 2025) [S24]Funder disruption that later hit H1-2026 PPDs
22 Sep 2025Special dividend paid (R3.4bn) [S1]Completes FY2025 distributions of R4.3bn
18 Nov 2025FY2025 trading statement [S1]Flags Piramal-driven headline loss
27 Nov 2025FY2025 results: revenue +6.0% to R25.1bn; NEPS +10.1%; final dividend 35 cents; FY2026 outlook (revenue c. 5%, occupancy 70%) [S1][S2]Base case for FY2026
Dec 2025Integrated Annual Report 2025 published [S26]Governance and ESG disclosures
Dec 2025Sizwe Hosmed curator reports restored access at Life facilities [S24]Partial normalisation
Dec 2025Remgro and IHL agree to split Mediclinic Holdings [S22]Competitor ownership change
22 Dec 2025Final dividend paid [S1]—
5 Feb 2026Adam Pyle's retirement announced (effective 1 Jun 2026) [S16]Loss of a 23-year executive
9 Feb 2026Constitutional Court defers NHI presidential-assent cases pending the public-participation cases [S23]NHI timeline extended
11 Feb 2026Sizwe Hosmed curator's mandate cancelled; replacement curator appointed [S24]Funder governance turbulence
19 Feb 2026AGM; Jacobs and Bolger retire; Abdullah becomes Clinical Committee chair [S3]Board refresh
20 Feb 2026President undertakes not to promulgate any NHI provisions before the Constitutional Court ruling [S23]Near-term NHI risk deferred
6 Mar 2026Lazard Asset Management increases its stake [S27]Institutional interest
9 Mar 2026US$148m paid to Piramal [S3]Major cash outflow; liability largely settled
12 Mar 2026R1.5bn notes issued (LHC07: R809m, JIBAR + 0.88%, due 2029; LHC08: R691m, JIBAR + 0.94%, due 2031) [S3]Refinancing at tight spreads
H1-2026RM2 regulatory and production milestone met (€4.9m due H2-2026) [S3]First post-sale LMI cash
5–7 May 2026Constitutional Court hears NHI public-participation challenges; judgment reserved [S23]Binary regulatory catalyst
7 May 2026H1-2026 trading statement (NEPS +6% to +10%) [S17]Pre-announcement
28 May 2026H1-2026 results: revenue +2.4%; NEPS +8.4%; interim dividend 23 cents; FY2026 guidance cut (revenue c. 2%, occupancy 68%); share price −5% to R10.80 [S3][S20]Guidance downgrade
Post-31 Mar 2026Platmed buy-out; Peglerae Hospital to 76% (R243m) [S3]Bolt-on consolidation
1 Jun 2026Pyle retires; Brett Mill joins the Life Healthcare Funding board [S3]Leadership transition
22 Jun 2026Interim dividend paid [S4]—
1 Jul 2026Remgro completes acquisition of 100% of Mediclinic Southern Africa (US$947m) [S22]A focused competitor with deep-pocketed ownership
6 Aug 2026Competition Commission approves the Bedford Gardens property acquisition [S18]Property ownership strategy
OngoingFresenius dispute (South African clawback R165m; Namibia consideration R163m) [S3]Potential cash and earnings impact
c. 26 Nov 2026 (expected)FY2026 results [S7]Next major catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: Southern Africa revenue rose from ZAR 19,030 Mn in FY2021 to ZAR 25,104 Mn in FY2025.
Life Healthcare Group Holdings Limited — Income Statement: Revenue & Gross Profit
Series (ZAR Mn)FY2021FY2022FY2023FY2024FY2025
Southern Africa revenue19,03019,97121,98523,67425,104
Group revenue as published26,88528,20622,64125,51925,104
Gross profit8,3545,8736,4816,6927,057

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Life Healthcare — Summarised Group results for the year ended 30 September 2025 and cash dividend declaration (27 Nov 2025) · SENS copy · trading statement
  2. S2Life Healthcare — FY2025 investor presentation (lifehealthcare.co.za)
  3. S3Life Healthcare — Unaudited Group interim results for the six months ended 31 March 2026 (results booklet) (lifehealthcare.co.za)
  4. S4Life Healthcare — Condensed unaudited interim results SENS announcement (28 May 2026) (lifehealthcare.co.za)
  5. S5Life Healthcare — FY2025 media release (lifehealthcare.co.za)
  6. S6Life Healthcare — H1-2026 media release (lifehealthcare.co.za)
  7. S7StockAnalysis.com (S&P Global Market Intelligence data) — income statement, balance sheet, cash flow, ratios · stockanalysis.com · stockanalysis.com · stockanalysis.com · stockanalysis.com
  8. S8MarketScreener / Zonebourse — segment data (ch.zonebourse.com)
  9. S9FY2024 results and coverage · sharedata.co.za · businesstech.co.za · dailydispatch.co.za · lifehealthcare.co.za · sharedata.co.za
  10. S10FY2023 results · lifehealthcare.co.za · lifehealthcare.co.za · sharedata.co.za
  11. S11FY2022 results and coverage · businessday.co.za · senspdf.jse.co.za
  12. S12LMI disposal · lifehealthcare.co.za · businessreport.co.za
  13. S13Daily Investor — "End of an era for South African private hospital giant" (May 2026) (dailyinvestor.com)
  14. S14Daily Investor — "Deal of the decade" (dailyinvestor.com)
  15. S15SENS 7 Aug 2025 — special dividend and board changes (sharedata.co.za)
  16. S16SENS 5 Feb 2026 — retirement of senior executive (senspdf.jse.co.za)
  17. S17SENS 7 May 2026 — trading update and statement H1-2026 (sharedata.co.za)
  18. S18IOL — Bedford Gardens deal approval (6 Aug 2026) (iol.co.za)
  19. S19BusinessTech — Life Paarl Valley Hospital (29 May 2026) · CEO profile and pay
  20. S20Interim coverage (28 May 2026) · ewn.co.za · businessday.co.za · ewn.co.za
  21. S21Netcare — FY2025 results · businessreport.co.za · H1-2026
  22. S22Remgro / Mediclinic · dailyinvestor.com · businesstech.co.za · senspdf.jse.co.za · oldmutual.co.za
  23. S23NHI litigation · ewn.co.za · moonstone.co.za · timeslive.co.za · businessday.co.za · businesstech.co.za · ewn.co.za
  24. S24Sizwe Hosmed · businessreport.co.za · sundayworld.co.za · moonstone.co.za
  25. S25Council for Medical Schemes 2024 Industry Report coverage · businessreport.co.za · theherald.co.za
  26. S26ESG and governance · lifehealthcare.co.za · lifehealthcare.co.za · sustainabilityreports.com · sustainabilityreports.com · sustainabilityreports.com · sustainabilityreports.com · lifehealthcare.co.za
  27. S27Ownership and consensus · simplywall.st · tradersunion.com · marketbeat.com · es.marketscreener.com
  28. S28Leadership history · businessday.co.za · cfo.co.za · businesslive.co.za · lifehealthcare.co.za
  29. S29Corporate history and miscellaneous · gasworld.com · lifehealthcare.co.za · busrep.co.za · iol.co.za · bloomberg.com · sharedata.co.za · sharedata.co.za · tw.tradingview.com
  30. S30Board SENS announcements · senspdf.jse.co.za · senspdf.jse.co.za
  31. S31Imaging and nuclear medicine · lifehealthcare.co.za
  32. S32Business Day — executive restructure (11 Apr 2024) (businessday.co.za)
  33. S33Creamer Media — LMI conditions precedent met (Jul 2025) (newsletter.en.creamermedia.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.